|Day Low/High||130.19 / 132.39|
|52 Wk Low/High||121.00 / 148.99|
Eight of these 11 trade ideas are in the green, with a few big winners.
Dollar strength is affecting the competitive advantage of U.S. companies around the globe, and it is a more insidious problem that most people recognize.
These companies are working to plant their flag in a new landscape.
Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?
There's a lot of runway left to adjust guidance numbers moving forward.
Volatility appears to be the most attractive play during the early portion of earnings season.
While the ongoing litigation could be seen as a deterrent to investment, I think the more interesting story is its upcoming AFib detection study with Apple.
Experienced traders could approach the long side carefully.
It's centered around a few themed negatives, all forcing their own various uncertainties into free market price discovery.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
JNJ's current pennant pattern creates the potential for a big move in the month of January.
Shares have fallen hard, despite the company's vehement scientific and legal defense.
Despite recent talc powder risks, the long-term earnings power of this 'Dividend King' has not deteriorated.
But even in bear markets you get spikes, usually short sharp ones.
We are absolutely due for a rip-your-face-off rally in the wake of entering a bear market.
Remember, though, playing defense is very different than leaving the stadium altogether.
These are currently situations where companies are facing serious lawsuits.
Are machines jumping on Johnson & Johnson's human risk headlines?
Putting J&J stock's selloff in a graphic illustrates the market's swift and violent reaction to the Reuters report.
Shares continue to fall on Monday after Friday's swift descent.
I find a lot of Reuters' claims hard to believe. Even more difficult to believe is the selloff.
Many analysts advise buying the shares on weakness because it's attractively priced.
JNJ ended the day and week in a vulnerable position and we are seeing further weakness today.
The market appears to still be spooked by JNJ as shares are set to open at their lowest level since July amid the Reuters articles fallout.
Now the unnerving thing about this market is that when it gets on a negative roll it blows through all convention.
While headline-chasing algorithms alter expected outcomes based on fundamental analysis, technical analysis remains valid.
Johnson & Johnson has survived some unfortunate news events in the past, but I would not take that as a good technical reason to hold the stock.